GANX
Overvalued by 77.8% based on the discounted cash flow analysis.
Market cap | $69.02 Million |
---|---|
Enterprise Value | $62.58 Million |
Dividend Yield | $- (-) |
Earnings per Share | $-0.89 |
Beta | 0.12 |
Outstanding Shares | 30,341,523 |
Return on Equity | - |
---|---|
Return on Assets | - |
Return on Invested Capital | - |
P/E Ratio | -3.13 |
---|---|
PEG | 10.93 |
Price to Sales | - |
Price to Book Ratio | - |
Enterprise Value to Revenue | - |
Enterprise Value to EBIT | -3.63 |
Enterprise Value to Net Income | -4 |
Total Debt to Enterprise | 0 |
Debt to Equity | 0.07 |
No data
No data
Gain Therapeutics, Inc. is redefining drug discovery with its See-Tx? target identification platform. By identifying and optimizing allosteric binding sites that have never before been targeted, Gain is unlocking new treatment options fo...